Received Jun 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
Pharmacist calling with a report of an adverse event regarding GARDASIL 9. Pharmacist stated that a patient's schedule was interrupted after their first dose was administered in 2022 and did not complete the vaccination series as recommended. Phar; the patient has not reported any medical concern regarding interruption in their series of Gardasil 9; This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date in 2022, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), 0.5 mL (route of administration, lot # and expiration date were not reported) for prophylaxis, however, the patient did not continued the vaccination schedule (inappropriate schedule of product administration). No adverse event was reported.